Real-world data on the effectiveness of TYRX and TauroPace for preventing CIED infections.

IF 1.3 American journal of cardiovascular disease Pub Date : 2024-08-25 eCollection Date: 2024-01-01 DOI:10.62347/DSHG1684
Andrea Messori, Maria Rita Romeo, Melania Rivano, Sabrina Trippoli
{"title":"Real-world data on the effectiveness of TYRX and TauroPace for preventing CIED infections.","authors":"Andrea Messori, Maria Rita Romeo, Melania Rivano, Sabrina Trippoli","doi":"10.62347/DSHG1684","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The implantation of cardiac implantable electronic devices (CIEDs) carries a known risk of infection. Two devices (TYRX and TauroPace) have been proposed to reduce this risk.</p><p><strong>Methods: </strong>The aim of our study was to compare the effectiveness of TauroPace and TYRX. Real-world comparative studies were included. Data analysis was based on reconstruction of individual patient data from Kaplan-Meier curves using an artificial intelligence algorithm. The endpoint was CIED infection or systemic infection. Statistical tests included heterogeneity assessment, superiority testing, and non-inferiority testing. The primary outcome measure was the hazard ratio (HR) with confidence interval (CI).</p><p><strong>Results: </strong>Our literature search identified two real-world studies suitable for our analysis. Follow-up was 12 months for TauroPace (654 patients) and 60 months for TYRX (872 patients), with a total of 2,083 controls. There was no heterogeneity among controls. Compared to the pooled control group, patients treated with TYRX or TauroPace had fewer CIED infections (HR, 0.3892; 95% CI, 0.2042-0.7419; P=0.00414; HR, 0.3313; 95% CI, 0.1005-1.0925; P=0.06958, respectively). When testing for non-inferiority of TauroPace vs. TYRX, the comparison yielded a HR of 0.8494 (in favor of TYRX) with a 90% CI of 0.27-2.63; this CI of TauroPace did not meet the non-inferiority criterion set at HR>0.75 (i.e., relative difference ≤25%).</p><p><strong>Conclusions: </strong>Both treatments had some important drawbacks. Regarding TYRX, more selective use in higher-risk patients should be advocated to improve its cost-effectiveness, but robust evidence is still lacking. Regarding TauroPace, our analysis testing for a non-inferiority margin of ≤25% did not meet this demonstration.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410787/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cardiovascular disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/DSHG1684","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The implantation of cardiac implantable electronic devices (CIEDs) carries a known risk of infection. Two devices (TYRX and TauroPace) have been proposed to reduce this risk.

Methods: The aim of our study was to compare the effectiveness of TauroPace and TYRX. Real-world comparative studies were included. Data analysis was based on reconstruction of individual patient data from Kaplan-Meier curves using an artificial intelligence algorithm. The endpoint was CIED infection or systemic infection. Statistical tests included heterogeneity assessment, superiority testing, and non-inferiority testing. The primary outcome measure was the hazard ratio (HR) with confidence interval (CI).

Results: Our literature search identified two real-world studies suitable for our analysis. Follow-up was 12 months for TauroPace (654 patients) and 60 months for TYRX (872 patients), with a total of 2,083 controls. There was no heterogeneity among controls. Compared to the pooled control group, patients treated with TYRX or TauroPace had fewer CIED infections (HR, 0.3892; 95% CI, 0.2042-0.7419; P=0.00414; HR, 0.3313; 95% CI, 0.1005-1.0925; P=0.06958, respectively). When testing for non-inferiority of TauroPace vs. TYRX, the comparison yielded a HR of 0.8494 (in favor of TYRX) with a 90% CI of 0.27-2.63; this CI of TauroPace did not meet the non-inferiority criterion set at HR>0.75 (i.e., relative difference ≤25%).

Conclusions: Both treatments had some important drawbacks. Regarding TYRX, more selective use in higher-risk patients should be advocated to improve its cost-effectiveness, but robust evidence is still lacking. Regarding TauroPace, our analysis testing for a non-inferiority margin of ≤25% did not meet this demonstration.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
关于 TYRX 和 TauroPace 预防 CIED 感染有效性的真实世界数据。
背景:植入心脏植入式电子设备(CIEDs)具有已知的感染风险。有两种设备(TYRX 和 TauroPace)被建议用于降低这一风险:我们的研究旨在比较 TauroPace 和 TYRX 的有效性。研究纳入了真实世界的比较研究。数据分析基于使用人工智能算法从 Kaplan-Meier 曲线重建的单个患者数据。终点为CIED感染或全身感染。统计检验包括异质性评估、优越性检验和非劣性检验。主要结果测量指标为危险比(HR)和置信区间(CI):我们的文献检索发现了两项适合我们分析的真实世界研究。TauroPace的随访时间为12个月(654名患者),TYRX的随访时间为60个月(872名患者),共有2083名对照组患者。对照组之间不存在异质性。与汇总对照组相比,接受TYRX或TauroPace治疗的患者CIED感染率较低(HR,0.3892;95% CI,0.2042-0.7419;P=0.00414;HR,0.3313;95% CI,0.1005-1.0925;P=0.06958)。在检测TauroPace与TYRX的非劣效性时,比较得出的HR为0.8494(TYRX更优),90% CI为0.27-2.63;TauroPace的这一CI不符合HR>0.75的非劣效性标准(即相对差异≤25%):结论:两种疗法都存在一些重要缺陷。关于TYRX,应提倡在高风险患者中更有选择性地使用,以提高其成本效益,但目前仍缺乏有力的证据。至于 TauroPace,我们的分析测试非劣效边际≤25%,但并未达到这一指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American journal of cardiovascular disease
American journal of cardiovascular disease CARDIAC & CARDIOVASCULAR SYSTEMS-
自引率
0.00%
发文量
21
期刊最新文献
A diagnostic prediction model for the early detection of heart failure following primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. A normal and particularly small (<35 mm) left atrial size measured during echocardiography suggests low likelihood of moderate or severe left ventricular systolic dysfunction. Exploring the impact of metabolites function on heart failure and coronary heart disease: insights from a Mendelian randomization (MR) study. Impact of risk factors on intervened and non-intervened coronary lesions. Investigating the effect of cancer medication in the development of Takotsubo cardiomyopathy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1